Saturday 17 October 2026 Export PAHC’s income statement to Excel — free account

Phibro Animal Health Corporation

PAHC Healthcare Drug Manufacturers Specialty & Generic

Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025. In the quarter to June 2026, revenue grew 4.77%, EPS grew 28.6%, free cash flow fell 35.7% and total debt rose 1.96%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

38.82 0.84 +2.21%

Follow PAHC

Alert me

Market cap: $1.5B
P/E: 15.8×
Fwd P/E: 11.1×
Dividend yield: 1.24%
F-score: 6/9
Altman Z: 2.95
Beneish M: −2.39
Dividend safety: 47/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.32

Total sells 28.15

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	7	3	6	6	4	3	1	—	—	—	—	—

Insider Ownership 48.40%

Capital & Financial Ratios $m

Market Cap 1,540.00

Revenue 1,518.09

Net Income 99.72

Free Cash Flow 9.87

Net Debt 650.80

Current Ratio 2.96

Debt/Equity 1.90

P/E ratio 15.78

Fwd P/E 11.10

P/S ratio 1.04

P/B ratio 4.08

Past 5Y EPS Growth 12.64%

This Y EPS Growth 8.70%

Next Y EPS Growth 9.79%

Next Y revenue growth 3.81%

Next 5Y EPS Growth 8.47%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 21.86%

10-year low 10-year high

P/S against its own 10 years 45.41%

10-year low 10-year high

P/B against its own 10 years 44.78%

10-year low 10-year high

EV/Sales against its own 10 years 47.48%

10-year low 10-year high

EV/FCF against its own 10 years 93.83%

10-year low 10-year high

Dividends

Payout Ratio 0.20

Annual Dividend Rate 0.48

Annual Dividend Yield 1.24%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	0.48	0.12 0.12 0.12
2025	0.48	0.12 0.12 0.12 0.12
2024	0.48	0.12 0.12 0.12 0.12
2023	0.48	0.12 0.12 0.12 0.12
2022	0.48	0.12 0.12 0.12 0.12
2021	0.48	0.12 0.12 0.12 0.12
2020	0.48	0.12 0.12 0.12 0.12
2019	0.48	0.12 0.12 0.12 0.12
2018	0.42	0.10 0.10 0.10 0.12
2017	0.40	0.10 0.10 0.10 0.10
2016	0.40	0.10 0.10 0.10 0.10

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	81	115	77	82
Receivables	163	169	228	239
Inventory	278	266	444	535
Other	63	51	61	80
	586	601	811	936

	2023	2024	2025	2026
Payables	74	86	138	127
ST’ Debt	22	30	16	25
Other	—	—	—	—
	176	204	293	316

Compound Annual Growth %

	10y	5y	3y
Sales	7.28%	12.74%	15.79%
Cash Flow	6.36%	7.38%	73.03%
Earnings	1.89%	12.89%	45.15%
Book Value	15.60%	10.08%	10.91%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	364	374	384	397	1,518
’25	260	309	348	379	1,296
’24	231	250	263	273	1,018
’23	233	245	246	255	978
’22	215	233	240	255	942
’21	195	206	212	220	833

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	9	19	16	24	69
’25	13	3	43	21	80
’24	16	32	11	28	88
’23	(11)	(2)	6	20	13
’22	4	20	6	2	32
’21	2	27	17	3	48

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(5)	8	1	5	10
’25	3	(5)	35	8	42
’24	9	21	2	15	46
’23	(34)	(12)	(2)	9	(38)
’22	(4)	12	(4)	(10)	(5)
’21	(6)	20	9	(4)	19

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0.65	0.67	0.59	0.53	2.43
’25	0.17	0.08	0.51	0.42	1.19
’24	(0.20)	0.03	0.21	0.02	0.06
’23	0.10	0.18	0.25	0.28	0.81
’22	0.16	0.43	0.44	0.18	1.21
’21	0.30	0.32	0.30	0.42	1.34

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	26.10	30.79	20.00	16.27	18.63	11.75	9.40	10.04	16.16	28.25	Analyst estimates 2027–2029 Powerpack
	High	40.25	54.62	36.98	29.38	31.00	22.16	16.52	25.98	46.42	60.08
People
People	Employees	1,400	1,500	1,600	2,500	1,725	1,860	1,920	1,940	2,475	2,605
	Revenue/emp, $m	0.55	0.55	0.52	0.32	0.48	0.51	0.51	0.52	0.52	0.58
Income, $m
Income, $m	Revenue	764	820	828	800	833	942	978	1,018	1,296	1,518
	Gross margin, %	32.48	32.55	31.96	32.10	32.56	30.29	30.50	30.77	30.85	33.76
	EBT	81	88	72	56	66	72	54	11	68	137
	EBT margin, %	10.54	10.74	8.64	6.94	7.98	7.68	5.53	1.07	5.25	9.05
	Net income	65	65	55	34	54	49	33	2	48	100
	Depreciation	27	28	28	33	33	33	35	37	48	54
Per share, $
Per share, $	Revenue	19.34	20.41	20.49	19.78	20.59	23.26	24.14	25.13	31.99	37.44
	Earnings	1.63	1.61	1.35	0.83	1.34	1.21	0.81	0.06	1.19	2.46
	Cash flow	2.49	1.74	1.17	1.47	1.19	0.78	0.33	2.16	1.98	1.70
	Capex	(0.53)	(0.46)	(0.74)	(0.84)	(0.72)	(0.91)	(1.28)	(1.02)	(0.95)	(1.46)
	Free cash flow	1.96	1.28	0.43	0.63	0.47	(0.13)	(0.95)	1.14	1.03	0.24
	Book value	3.82	4.60	5.35	4.65	5.89	6.48	6.97	6.34	7.05	9.51
	Shares, m	40	40	40	40	40	41	41	41	41	41
Valuation, ×
Valuation, ×	P/E	22.59	29.10	23.25	32.04	21.55	15.81	16.91	284.00	21.46	12.76
	P/S	1.92	2.30	1.54	1.33	1.40	0.82	0.57	0.68	0.80	0.84
	P/B	9.69	10.18	5.92	5.65	4.90	2.95	1.96	2.69	3.62	3.30
	EV/Sales	2.25	2.58	1.84	1.70	1.76	1.18	0.97	1.05	1.29	1.27
	EV/FCF	22.21	41.11	88.11	53.69	77.31	(206.95)	(24.65)	22.95	40.08	195.01
Cash, $m
Cash, $m	Operating cash flow	98	70	47	59	48	32	13	88	80	69
	Capex	(21)	(19)	(30)	(34)	(29)	(37)	(52)	(41)	(38)	(59)
	Free cash flow	78	51	17	25	19	(5)	(38)	46	42	10
Balance, $m
Balance, $m	Working capital	248	272	312	295	335	375	410	397	517	619
	Total debt	313	312	326	387	392	433	475	488	719	733
	Net debt	257	233	245	296	299	342	394	373	642	651
	Shareholders’ equity	151	185	216	188	239	262	283	257	286	385
Returns, %
Returns, %	ROA	10.50	10.02	7.83	4.44	6.69	5.55	3.43	0.25	4.12	6.97
	ROIC	14.99	14.79	11.29	8.94	8.71	8.17	6.64	5.29	7.45	11.72
	ROE	53.48	38.61	27.29	16.60	25.49	19.63	11.97	0.90	17.80	29.72

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%
ETON Eton Pharmaceuticals, Inc.	$1.5B	107×	40.3×	+98.59% (above 0%: growing)	n/m	−8.78% (below 0%: shrinking)	67.61%	34.04%	Compare
PCRX Pacira BioSciences, Inc.	$1.5B	104×	33.7×	+6.24% (above 0%: growing)	n/m	+502.51% (above 0%: growing)	77.05%	2.22%	Compare
CRON Cronos Group Inc.	$1.2B	16.1×	32.2×	+58.44% (above 0%: growing)	n/m	+2,279.22% (above 0%: growing)	53.67%	13.97%	Compare
AMPH Amphastar Pharmaceuticals, Inc.	$1.1B	14.9×	14.7×	+5.44% (above 0%: growing)	+4.55% (above 0%: growing)	+87.61% (above 0%: growing)	50.83%	21.60%	Compare
Median of peers	$1.6B	16.1×	32.2×	+31.17%	+99.57%	+120.42%	64.98%	14.59%

All 86 Drug Manufacturers Specialty & Generic stocks →

Phibro Animal Health Corporation (PAHC) key facts

Strength: Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025.
Strength: Net income was $99.7 million, or $2.46 per share (basic), a net margin of 6.57%.
Phibro Animal Health Corporation (PAHC) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PAHC traded at $38.82, a market capitalization of $1.5 billion.
At that price the stock trades at 15.8× trailing-twelve-month earnings and 1.0× sales; its P/E is higher than 22% of its own readings over the past ten years.
Phibro Animal Health Corporation pays an annual dividend of $0.48 per share, a yield of 1.24%, with a payout ratio of 19.7%.
Return on equity was 29.7% and debt-to-equity 1.90.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.95 (grey zone) for fiscal 2026.